Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. The company is headquartered in Durham, North Carolina.
| Revenue (TTM) | $2.67B |
| Gross Profit (TTM) | $533.40M |
| EBITDA | $118.10M |
| Operating Margin | 2.27% |
| Return on Equity | -12.30% |
| Return on Assets | 1.03% |
| Revenue/Share (TTM) | $28.31 |
| Book Value | $5.52 |
| Price-to-Book | 3.71 |
| Price-to-Sales (TTM) | 0.80 |
| EV/Revenue | 1.077 |
| EV/EBITDA | 26.64 |
| Quarterly Earnings Growth (YoY) | -57.40% |
| Quarterly Revenue Growth (YoY) | -1.40% |
| Shares Outstanding | $96.50M |
| Float | $95.38M |
| % Insiders | 1.21% |
| % Institutions | 109.23% |
Volatility is currently expanding
Fortrea NASDAQ: FTRE reported third-quarter 2026 revenue of $691.5 million, down 1.4% from a year earlier but up 2.0% sequentially, as the contract research organization cited improving demand, stronger operational execution and continued cost discipline.
Fortrea Holdings Inc. (FTRE) Q3 2026 Earnings Call Transcript
Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.12 per share a year ago.
Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation
DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations Tracy Krumme will participate in the following conference:
Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Highlights Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials Adds a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, Texas; and a biospecimen storage facility in Pflugerville, Texas Expands Fortrea's early clinical development capacity to more than 570 beds globally and adds dedicated large and small molecule bioanalytical capabilities Enables more integrated execution of early-phase studies by reducing operational handoffs between clinical and bioanalytical functions Strengthens Fortrea's end-to-end clinical development platform supporting clients from first-in-human studies through Phase IV and post-approval evidence generation Supports Fortrea's growth strategy by scaling early clinical development capabilities, increasing clinical research unit capacity and enhancing the company's ability to create long-term value for shareholders Provides continuity of operations, study delivery and client support throughout the transition through a strategic alliance agreement between the companies DURHAM, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced it has completed its acquisition of the Early Phase Services division from Worldwide Clinical Trials.
Small-cap stocks have surrendered their lead over large caps in 2026 amid rising Treasury yields, but historical data shows small caps can rebound strongly when yields decline. Bank of America strategists see potential for a small-cap rebound if the 10-year Treasury yield peaks around their year-end forecast of 5%. I highlight three fundamentally strong small-cap stocks that have outperformed the market since the Russell 2000's recent high, defying the index's broader weakness.
DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FTRE and any ticker you trade — then tracks every position and per-strategy win rate.
